Business
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corpora...
About this update from Innocan Pharma Corporation
[{"type":"text","content":"Innocan Pharma Announces Launch of CBD Veterinary Commercialization TeamHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the \"Company\" or \"Innocan\"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, stated, \"We are excited to announce the appointment of a dedicated internal team covering the financial, scientific, and legal aspects required to engage with prospective clients in the veterinary field. Our goal is to commercialize, partner, and/or sell Innocan's intellectual property portfolio to veterinary indications. We believe there is significant potential in the veterinary market for our CBD-based products.\"CBD has been shown to have a wide range of therapeutic properties, including anti-inflammatory, analgesic, and anti-anxiety effects. The veterinary market is an important sector that can benefit from the potential therapeutic effects of CBD. The appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field in order to explore potential collaborations and commercialization opportunities.Innocan's innovative CBD-based products have previously demonstrated promise in human clinical trials, and the Company is eager to explore the potential for these products in the veterinary field. The Company believes that the veterinary market represents a significant opportunity for growth, and it looks forward to working with potential collaborators to bring these products to market.About InnocanInnocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood strea...